Navigation Links
Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
Date:5/29/2012

HELSINKI, Finland, May 29, 2012 /PRNewswire/ --

Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors. The first patients have already completed the safety assessment part of the study.

"We are proud to be the first clinic in Northern Europe to start a clinical study with oncolytic viruses," comments the Principal Investigator of the study, Chief Physician of Docrates Hospital, Dr. Timo Joensuu. "We believe that oncolytic adenoviruses, a generally well tolerated therapy, will have an important role in the future of cancer treatments."

"In our earlier experimental use the treatment has appeared to be safe for cancer patients. We really look forward to establishing the same safety in a clinical study with a more advanced dosing schedule. We believe the schedule used in the trial will also eventually contribute to the efficacy of the therapy," adds Helsinki University's Research Professor Akseli Hemminki, co-inventor of CGTG-102 and co-founder of Oncos Therapeutics.

The patient data cumulated over the past 5 years have contributed significantly to the design of the entire clinical development program of the company. "In addition to existing clinical safety data, which is unique to this stage of development, we also have a wealth of supportive data to guide the selection of target tumor types, optimal treatment administration, and other essential elements including clues regarding mechanism of action and possible biomarkers. We are very excited about the design of our entire development program driven by clinical data," summarizes Chief Medical Officer and Head of Research of Oncos Therapeutics, Mikael von Euler.

About Oncos Therapeutics

Oncos Therapeutics, based in Helsinki, Finland, develops novel cancer therapies based on its next generation oncolytic viruses. Its clinical development program of the lead virus CGTG-102 is based on clinical experience from an experimental treatment program with ten different oncolytic viruses, and is planned to expand into several countries in the near future. For more information about Oncos visit http://www.oncos.com.


'/>"/>
SOURCE Oncos Therapeutics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
10. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental Implants ... ... for Dental Implants in US$ Million. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through 2022. ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News ... ... publisher of cannabis market research, the legal cannabis market is ... through 2021, despite conflicting signals from the current presidential administration. ... that the two biggest drivers of growth in this industry ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Deep ... to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines ... deep learning solutions within the healthcare domain. Primarily driven by the ... solution to generate relevant insights from medical data. ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/24/2017)... ... , ... “The Communion of Saints: A Pastor’s Potpourri of ... across the United States. “The Communion of Saints” is the creation of ... congregations in seven states throughout his long career of devotion to the church. ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World ... that there could be four million Zika-related cases in the Americas within the next ... of US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The physicians of ... in the greater Houston Area. The new location is located at 2255 E. Mossy ... in Springwoods Village. This newest location will provide patients living in the north Houston ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
Breaking Medicine News(10 mins):